

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6258932

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MICURX PHARMACEUTICALS, INC. (CAYMAN)	07/23/2020
RECEIVING PARTY DATA	
Name:	MICURX (HK) LTD.
Street Address:	14TH FLOOR, GOLDEN CENTRE, 188 DES VOEUX ROAD CENTRAL
City:	HONG KONG
State/Country:	HONG KONG
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	8178683
Patent Number:	9382276
Patent Number:	8530452
Patent Number:	9771394
CORRESPONDENCE DATA	
Fax Number:	(415)393-9887
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(415) 954-0200
Email:	tanisha.lawrence-caceres@squirepb.com
Correspondent Name:	SQUIRE PATTON BOGGS (US) LLP
Address Line 1:	275 BATTERY STREET, SUITE 2600
Address Line 2:	ATTN: JANICE V. RICE
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94111
ATTORNEY DOCKET NUMBER:	107381.23; .72; .57; .75
NAME OF SUBMITTER:	JANICE V. RICE
SIGNATURE:	/JANICE V. RICE/
DATE SIGNED:	08/19/2020
Total Attachments: 4	
source=112738_00023_Cayman_Islands_to_Hong_Kong#page1.tif	
source=112738_00023_Cayman_Islands_to_Hong_Kong#page2.tif	
source=112738_00023_Cayman_Islands_to_Hong_Kong#page3.tif	

PATENT ASSIGNMENT

This Assignment of Patents ("Assignment"), including all schedules attached hereto, is made effective on the date of execution of the last party to sign.

WHEREAS, **MICURX PHARMACEUTICALS, INC. (Cayman)**, a corporation organized and existing under the laws of Cayman Islands, and having an office for the transaction of business at Walkers Corporate Limited (c/o MicuRx Pharmaceuticals, Inc.), Cayman Corporate Centre, 27 Hospital Road, George Town, Grand Cayman KY1-9008, Cayman Islands, ASSIGNOR, has been assigned the entire right, title and interest in the inventions and applications in Schedule A, through assignments including an assignment executed by MicuRx Pharmaceuticals, Inc. (U.S.A.) on _____, before the execution of the present Patent Assignment;

and WHEREAS, **MICURX (HK) LTD.**, a corporation organized and existing under the laws of Hong Kong, and having an office for the transaction of business at 14th Floor, Golden Centre, 188 Des Voeux Road, Central, Hong Kong, ASSIGNEE, is desirous of obtaining ASSIGNOR's entire right, title and interest in, to and under the inventions and the applications in Schedule A.

NOW, THEREFORE, for good and valuable consideration, including shares in MicuRx (HK) Ltd., the receipt of which is hereby acknowledged, ASSIGNOR, has sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, unto the ASSIGNEE, its successors, legal representatives and assigns, ASSIGNOR's entire right, title and interest in, to and under the inventions and the applications in Schedule A, and all applications claiming priority thereto and all divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for the inventions in the United States or in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from the applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for the inventions in the United States or in any country or countries foreign to the United States and all extensions, renewals and reissues thereof;

AND ASSIGNOR HEREBY authorizes and requests the Commissioner for Patents of the United States and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this Assignment;

AND ASSIGNOR HEREBY covenants and agrees that ASSIGNOR has full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed, and will not execute, any agreement in conflict herewith;

AND ASSIGNOR HEREBY further covenants and agrees to execute, or cause the inventors to execute, such further documents reasonably required by Assignee to secure and enforce the rights granted to ASSIGNEE under this Assignment; to do generally everything possible to aid the ASSIGNEE, its successors, legal representatives and assigns, to secure and enforce proper protection for the invention in all countries.

This Assignment may be executed in counterparts, each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party hereto and delivered to the other party, it being understood that each party need not sign the same counterpart. This Assignment may be executed and delivered by facsimile or by an electronic scan delivered by electronic mail.

[Remainder of this page is intentionally left blank.]

IN TESTIMONY WHEREOF, ASSIGNOR and ASSIGNEE have caused this Assignment to be executed by their duly authorized officers as of the date of the last party to sign.

Assigned by MicuRx Pharmaceuticals, Inc.
(Cayman)

Date 07/23/2020


Zhengyu Yuan, Chief Executive Officer

Executed at


Shanghai China
City, State, Country

[Remainder of this page is intentionally left blank.]

Accepted by MICURX (HK) LTD.

For and on behalf of
MicuRx (HK) Limited

Date July 23, 2020


.....
Zhiyue Li, Director

Executed at

Hong Kong

.....
City, State, Country

[Remainder of this page is intentionally left blank.]

No.	Patent Name	Status	Application Date	Patent Number	Grant Date
1	Antimicrobial O-F-phenyl-oxazolidinone for treatment of bacterial infections	Granted	2008.08.06	US8178683	2012.05.15
2	Antimicrobial O-F-phenyl-oxazolidinone for treatment of bacterial infections	Granted	2008.08.06	CA2695616	2015.11.11
3	Antimicrobial O-F-phenyl-oxazolidinone for treatment of bacterial infections	Granted	2008.08.06	JP5455986	2014.01.17
4	Antimicrobial O-F-phenyl-oxazolidinone for treatment of bacterial infections	Granted	2008.08.06	EP2185549 (France, Germany, United Kingdom)	2018.10.3
5	Therapeutic water soluble (O-carbonyl) aminophosphate prodrugs	Granted	2015.02.20	US9382276	2016.07.05
6	Therapeutic water soluble (O-carbonyl) aminophosphate prodrugs	Pending	2015.02.20	EP15708079.7	N/A
7	Therapeutic water soluble (O-carbonyl) aminophosphate prodrugs	Pending	2015.02.20	JP2016-570920	N/A
8	Therapeutic water soluble (O-carbonyl) aminophosphate prodrugs	Pending	2015.02.20	KR20167022835	N/A
9	Therapeutic water soluble (O-carbonyl) aminophosphate prodrugs	Pending	2015.02.20	IN201617031055	N/A
10	Therapeutic water soluble (O-carbonyl) aminophosphate prodrugs	Pending	2015.02.20	CA2939098	N/A
11	Tricyclic Boron Compounds for Antimicrobial Therapy	Granted	2012.12.20	US8530452	2013.9.10
12	Antimicrobial polymyxins for treatment of bacterial infections	Granted	2015.12.16	US9771394	2017.09.26
13	Antimicrobial polymyxins for treatment of bacterial infections	Pending	2015.12.16	CA2970546	N/A
14	Antimicrobial polymyxins for treatment of bacterial infections	Pending	2015.12.16	EP15840980.5	N/A
15	Antimicrobial polymyxins for treatment of bacterial infections	Pending	2015.12.16	IN201717023819	N/A
16	Antimicrobial polymyxins for treatment of bacterial infections	Pending	2015.12.16	JP2017-532053	N/A
17	Antimicrobial polymyxins for treatment of bacterial infections	Pending	2015.12.16	KR10-2017-7019383	N/A